Testosterone Cypionate Adolescent (12 to 17) Dosing

Why Adolescent Dosing Differs from Adult Protocols

Testosterone cypionate prescribing for patients aged 12 to 17 follows a fundamentally different logic than adult replacement. Open growth plates, incomplete sexual maturation, and still-developing neurobiology mean that both underdosing and overdosing carry distinct risks not present in adults.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "In adolescent males with hypogonadism, we recommend initiating testosterone at low doses and gradually increasing to adult replacement levels over a period of 2 to 3 years to mimic the tempo of normal puberty" [2]. This graduated approach protects skeletal maturation. Supraphysiologic testosterone levels accelerate epiphyseal fusion, which can permanently reduce adult height [1]. Conversely, prolonged hypogonadism during adolescence delays bone mineral accrual, secondary sex characteristic development, and psychosocial adjustment [3].

The FDA prescribing information for Depo-Testosterone lists male hypogonadism as an approved indication without specifying an adolescent-specific dose table, leaving titration decisions to the prescribing clinician based on Tanner staging and bone age assessments [4]. Pediatric endocrinologists typically categorize adolescent testosterone use into three clinical buckets: constitutional delay of growth and puberty (CDGP), confirmed permanent hypogonadism, and gender-affirming hormone therapy. Each category calls for a different starting dose, duration, and monitoring cadence.

Constitutional Delay of Growth and Puberty: Short-Course Dosing

For boys aged 14 and older with CDGP, testosterone cypionate is prescribed as a time-limited "priming" course to jump-start puberty, not as indefinite replacement. The standard protocol is 50 to 100 mg intramuscularly once per month for 3 to 6 months [3].

A 2012 review in the New England Journal of Medicine (Palmert and Dunkel) reported that approximately 2% of adolescents experience CDGP, making it the most common reason for referral to pediatric endocrinology for delayed puberty [3]. Low-dose testosterone courses in these patients typically produce testicular enlargement and early virilization within 3 to 4 months, after which endogenous puberty takes over. If no testicular growth occurs after a full 6-month course, the diagnosis shifts toward permanent hypogonadism, and the treatment plan changes accordingly.

Doses above 100 mg per month in the short-course setting are rarely justified. Higher doses risk advancing bone age disproportionately to chronologic age. Clinicians track this with serial wrist radiographs (Greulich-Pyle atlas) at baseline and after each 3-month cycle. A bone age advance of more than 1 year beyond chronologic age during treatment warrants dose reduction or temporary discontinuation [6].

The goal is reassurance and initiation. Not full replacement. Once endogenous hypothalamic-pituitary-gonadal (HPG) axis activation is confirmed by a morning testosterone level above 150 ng/dL and testicular volume exceeding 4 mL, exogenous testosterone is stopped.

Confirmed Hypogonadism: Long-Term Replacement Titration

When primary or secondary hypogonadism is confirmed through repeat early-morning testosterone levels below 150 ng/dL, elevated or inappropriately normal LH/FSH, and (for primary hypogonadism) karyotype or genetic testing, long-term testosterone replacement is indicated [2].

The titration schedule mimics physiologic puberty over a 2- to 3-year window:

Months 1 through 6: 50 mg intramuscularly every 4 weeks. This low dose approximates early-pubertal testosterone concentrations of 100 to 300 ng/dL and allows time to confirm tolerability, monitor bone age, and assess psychological response [2].

Months 7 through 12: Increase to 50 mg every 2 weeks (or 100 mg every 4 weeks, depending on trough levels). Target trough testosterone of 200 to 400 ng/dL.

Year 2: Increase to 75 to 100 mg every 2 weeks. Monitor for acne severity, hematocrit changes, and mood disturbances. Bone age X-rays every 6 months.

Year 3 and beyond: Titrate toward adult replacement doses of 100 to 200 mg every 7 to 14 days once Tanner stage V is reached and near-final adult height is confirmed by bone age [greater than or equal to] 16 years.

The Endocrine Society 2018 guideline recommends checking trough testosterone 7 days after the most recent injection once on a stable dose, aiming for 300 to 700 ng/dL in patients approaching adult Tanner staging [2]. Hematocrit should stay below 54%; a reading above this level requires dose reduction or temporary hold to mitigate polycythemia-driven thrombotic risk.

Klinefelter syndrome (47,XXY) accounts for a significant proportion of adolescent primary hypogonadism cases, with an estimated prevalence of 1 in 660 live male births [6]. These patients often need lifelong replacement and benefit from starting testosterone at age 12 to 14 if puberty has not spontaneously initiated by then.

Gender-Affirming Testosterone Therapy in Adolescents

The Endocrine Society 2017 guideline on gender-dysphoric/gender-incongruent persons recommends that testosterone therapy in transgender males begin after diagnostic criteria are met and, for minors, after multidisciplinary evaluation [5]. Testosterone cypionate is one of the most commonly prescribed formulations in this setting.

Dr. Wylie Hembree, lead author of the 2017 Endocrine Society guideline, wrote: "We suggest that clinicians begin pubertal hormone treatment using a gradually increasing dose schedule" for gender-incongruent adolescents who meet eligibility criteria [5]. Typical starting doses range from 25 to 50 mg subcutaneously or intramuscularly every 2 weeks, with increases of 25 mg every 6 months based on clinical virilization and serum testosterone levels [5].

Target testosterone levels match those of cisgender male peers at equivalent Tanner stages. By 18 to 24 months, most patients reach adult male reference ranges of 300 to 1,000 ng/dL. Monitoring mirrors the hypogonadism protocol: CBC, metabolic panel, lipids, and testosterone levels every 3 months during the first year, then every 6 to 12 months once stable [5].

Bone density screening via DXA is recommended at baseline and every 1 to 2 years, particularly for patients who received GnRH agonist suppression before starting testosterone. The period between puberty suppression and cross-sex hormone initiation is a window of reduced bone mineral accrual, and testosterone therapy helps recover bone density once started [5].

Injection Route: Intramuscular vs. Subcutaneous

The FDA-approved label for Depo-Testosterone specifies intramuscular injection into the gluteal muscle [4]. Subcutaneous administration is used off-label but has gained acceptance in clinical practice, particularly for adolescents who find deep IM injections distressing.

A 2014 study by Spratt et al. found that subcutaneous testosterone cypionate produced comparable steady-state testosterone levels to intramuscular injection, with no significant difference in hematocrit elevation or adverse events (N=63) [7]. Subcutaneous injection uses a shorter needle (typically 25-gauge, 5/8 inch vs. 22-gauge, 1.5 inch for IM), which may improve adherence in younger patients.

For either route, rotating injection sites reduces the risk of local reactions. Intramuscular sites include the ventrogluteal and vastus lateralis. Subcutaneous sites include the abdomen and anterior thigh. Injection-site pain occurs in roughly 10% of patients regardless of route [4].

Monitoring: What to Track and When

Safe adolescent testosterone therapy requires a structured monitoring schedule that extends well beyond serum testosterone levels. The following labs and assessments should be performed at baseline and at regular intervals.

Baseline (before first injection): Morning testosterone (two separate days), LH, FSH, prolactin, karyotype (if primary hypogonadism suspected), bone age X-ray, CBC, comprehensive metabolic panel, fasting lipids, and a validated mental health screening tool [2] [6].

Every 3 months (first year): Trough testosterone (drawn 7 days post-injection on a biweekly schedule), CBC with hematocrit, LFTs, and clinical assessment of virilization using Tanner staging. Height and weight at every visit [2].

Every 6 months: Bone age X-ray and fasting lipid panel. Growth velocity calculation. Assessment of acne, mood, and behavioral changes.

Annually: DXA scan if risk factors for low bone density are present. Reevaluation of the underlying diagnosis and treatment goals. Discussion about fertility preservation, since exogenous testosterone suppresses spermatogenesis [2].

Hematocrit is the single most important safety lab. In the T-Trials (N=790 testosterone-treated men), the most common adverse finding was an increase in hematocrit above 54%, occurring in 3.4% of participants [3a]. While these data come from men aged 65 and older, the physiologic mechanism (erythropoietin stimulation) is identical in adolescents, and the hematocrit threshold for intervention is the same [2].

Mental Health Considerations

Testosterone therapy during adolescence intersects directly with neurodevelopment. Both hypogonadism and testosterone replacement can affect mood, cognition, and behavior, making structured psychological monitoring a non-negotiable part of the treatment plan.

Untreated hypogonadism in adolescent males is associated with increased rates of depression, social withdrawal, and poor self-esteem [6]. Testosterone replacement generally improves psychosocial outcomes, but dose-dependent mood effects can occur. Irritability, aggression, and anxiety have been reported at supraphysiologic levels [2].

The Endocrine Society guideline recommends that "clinicians monitor patients receiving testosterone for symptoms of mood disorders and refer for psychiatric evaluation when indicated" [2]. For adolescent patients, this translates to a validated screening tool (PHQ-A, GAD-7, or equivalent) at baseline and every 3 to 6 months during the first year. Parents and caregivers should be educated about warning signs.

Sleep quality also warrants attention. Testosterone influences sleep architecture and can worsen undiagnosed obstructive sleep apnea. Any adolescent patient reporting new-onset snoring, daytime somnolence, or fatigue on testosterone should be referred for polysomnography [2].

Fertility Preservation Before Starting Therapy

Exogenous testosterone suppresses gonadotropin secretion, which in turn reduces or halts sperm production. This is a critical counseling point for all adolescents starting testosterone, regardless of the clinical indication.

For patients with confirmed hypogonadism who may want biological children, sperm banking should be discussed before the first injection [2]. Spermatogenesis may not yet be established in early-pubertal males, which complicates preservation. In Klinefelter syndrome, testicular sperm extraction (micro-TESE) has a retrieval rate of approximately 40 to 60% when performed before prolonged exogenous testosterone exposure [8].

For transgender male adolescents, the 2017 Endocrine Society guideline states that fertility preservation options should be discussed with patients and families prior to initiating testosterone, acknowledging that oocyte or tissue cryopreservation may be desired [5]. The conversation should be documented in the medical record.

Recovery of spermatogenesis after testosterone discontinuation is variable. Some adult studies show recovery within 6 to 12 months, but data in adolescents are limited. The safest assumption is that testosterone therapy carries a risk of permanent fertility impairment, and preservation should happen early [2].

When to Refer to a Pediatric Endocrinologist

Not every adolescent with a low testosterone level needs specialty care. A single low morning testosterone in a 13-year-old with a family history of late puberty and normal growth velocity may simply need reassurance and a 6-month follow-up. Referral is appropriate when any of the following are present:

Testicular volume below 4 mL after age 14. No pubertal progression after 6 months of observation. Suspected Klinefelter syndrome or other genetic cause. Bone age more than 2 years behind chronologic age. Coexisting pituitary pathology (elevated prolactin, visual field changes, midline defects). Need for gender-affirming hormone therapy initiation in a minor. Previous use of GnRH agonist therapy requiring transition to testosterone [2] [6].

Primary care clinicians should avoid initiating testosterone in adolescents without first confirming the diagnosis with two early-morning serum testosterone levels drawn on separate days and, when indicated, pituitary MRI and genetic testing [2]. Premature treatment of a patient with constitutional delay can suppress the HPG axis unnecessarily and delay the natural onset of puberty once the short course ends.